Thermo Fisher Scientific, Danaher, AbbVie, Moderna, Kazia Therapeutics, Vertex Pharmaceuticals, and IQVIA are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks refer to stocks of companies in the biotechnology industry that are involved in researching, developing, and commercializing products related to healthcare, agriculture, or other biological sciences. These stocks can be highly volatile due to factors like clinical trial results, regulatory approvals, and market forces that influence the success or failure of biotech companies. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Thermo Fisher Scientific stock traded up $37.09 during mid-day trading on Thursday, hitting $605.32. 1,462,671 shares of the company’s stock traded hands, compared to its average volume of 2,011,679. The stock has a market cap of $231.53 billion, a price-to-earnings ratio of 37.94, a P/E/G ratio of 3.82 and a beta of 0.76. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. The firm has a 50 day simple moving average of $537.83 and a two-hundred day simple moving average of $570.33. Thermo Fisher Scientific has a fifty-two week low of $493.30 and a fifty-two week high of $627.88.
Read Our Latest Research Report on TMO
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Shares of NYSE:DHR traded down $1.00 during trading on Thursday, reaching $222.73. 2,174,924 shares of the stock were exchanged, compared to its average volume of 3,385,345. The firm has a market cap of $160.88 billion, a PE ratio of 42.52, a PEG ratio of 4.43 and a beta of 0.83. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. Danaher has a 12 month low of $223.00 and a 12 month high of $281.70. The stock has a 50-day moving average price of $235.89 and a 200-day moving average price of $253.45.
Read Our Latest Research Report on DHR
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
NYSE ABBV traded down $0.02 on Thursday, reaching $175.24. The stock had a trading volume of 1,705,043 shares, compared to its average volume of 5,728,507. The company has a debt-to-equity ratio of 9.64, a current ratio of 0.65 and a quick ratio of 0.54. The company has a market cap of $309.67 billion, a P/E ratio of 60.79, a price-to-earnings-growth ratio of 1.68 and a beta of 0.58. The firm has a fifty day moving average of $176.37 and a two-hundred day moving average of $184.90. AbbVie has a 1-year low of $153.58 and a 1-year high of $207.32.
Read Our Latest Research Report on ABBV
Moderna (MRNA)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Shares of MRNA stock traded up $1.12 on Thursday, hitting $41.84. The company’s stock had a trading volume of 4,806,568 shares, compared to its average volume of 12,517,176. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The company has a market capitalization of $16.10 billion, a PE ratio of -7.23 and a beta of 1.60. Moderna has a fifty-two week low of $31.94 and a fifty-two week high of $170.47. The stock’s 50 day moving average is $40.87 and its 200-day moving average is $62.03.
Read Our Latest Research Report on MRNA
Kazia Therapeutics (KZIA)
Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.
Shares of NASDAQ KZIA traded up $0.70 during midday trading on Thursday, reaching $2.08. The company’s stock had a trading volume of 93,492,063 shares, compared to its average volume of 4,981,501. Kazia Therapeutics has a fifty-two week low of $1.32 and a fifty-two week high of $15.80. The business’s 50 day moving average price is $2.97 and its two-hundred day moving average price is $3.89.
Read Our Latest Research Report on KZIA
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Shares of NASDAQ:VRTX traded down $0.50 during trading on Thursday, reaching $441.02. 332,596 shares of the company traded hands, compared to its average volume of 1,433,946. The firm has a market capitalization of $113.58 billion, a PE ratio of -221.81, a PEG ratio of 2.20 and a beta of 0.40. Vertex Pharmaceuticals has a 52 week low of $377.85 and a 52 week high of $519.88. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. The company’s 50 day moving average is $434.56 and its two-hundred day moving average is $463.49.
Read Our Latest Research Report on VRTX
IQVIA (IQV)
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
IQV stock traded up $2.11 during midday trading on Thursday, reaching $200.18. The company had a trading volume of 646,897 shares, compared to its average volume of 1,324,062. The company has a market capitalization of $36.33 billion, a price-to-earnings ratio of 26.29, a price-to-earnings-growth ratio of 2.14 and a beta of 1.48. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA has a 1-year low of $187.62 and a 1-year high of $261.73. The stock has a 50 day moving average price of $200.34 and a 200-day moving average price of $220.78.
Read Our Latest Research Report on IQV
Further Reading
- MarketBeat’s Top Five Stocks to Own in January 2025
- Is Tonix Pharmaceuticals the Next Biotech Breakout?
- DeepSeek Dip: Is the Nuclear Energy Sell-Off a Buying Opportunity
- ASML: Strengths and Upside Remain Despite DeepSeek Worries
- Royal Caribbean Soars, But Smooth Sailing Isn’t Guaranteed
- Kimberly-Clark: A Regal Opportunity in This Dividend King